KIACTA™ - Sarcoidosis
KIACTA™ (eprodisate disodium) is a novel oral treatment in development for the treatment of pulmonary sarcoidosis. Kiacta™ has been previously studied with a very clean safety profile in two Phase 3 studies in AA Renal Amyloidosis with exposure over greater than 10 years in some patients. Based on the safety profile of the product and strong scientific rationale for its use in pulmonary sarcoidosis, the FDA has indicated its support for one registrational trial, dependent on its review of the final results. An acquiror of Kiacta™ Sarl will enjoy freedom to commercialize the product worldwide. This product directly treats sarcoidosis, an orphan disease. We are currently in discussions regarding the sale of this product.